Mark N. Lampert
@Bvf Inc Il
Latest period2024 - Q3ReportedManaged Assets$3.418BTotal holdings55
Assets growth rate-4.19%Assets growth rate (2-Q avg)-3.05%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Bvf Inc Il's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 55 positions.
Assets under management
The assets under management (AUM) of Bvf Inc Il over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 3.418B in assets, with a quarterly growth rate of -4.19% and a 2-quarter average growth rate of -3.05%. The portfolio is managed by Mark N. Lampert, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
PTGXProtagonist Therapeutics Inc
| 2.44% | $83.258M 1.85M shares@ $45.0 avg price | Decreased -44.26% |
FDMT4d Molecular Therapeutics In
| 2.34% | $79.806M 7.383M shares@ $10.81 avg price | Increased 88.22% |
ACIUAc Immune Sa
| 2.16% | $73.795M 19.522M shares@ $3.78 avg price | Increased 3.66% |
GHRSGh Research Plc
| 2.04% | $69.577M 10.4M shares@ $6.69 avg price | |
KURAKura Oncology Inc
| 1.93% | $65.884M 3.372M shares@ $19.55 avg price | Decreased -17.4% |
THRDThird Harmonic Bio Inc
| 1.74% | $59.158M 4.366M shares@ $13.55 avg price | |
IONSIonis Pharmaceuticals Inc
| 1.71% | $58.162M 1.452M shares@ $40.07 avg price | Decreased -54.43% |
ZYMEZymeworks Inc
| 1.7% | $57.83M 4.608M shares@ $12.55 avg price | Decreased -21.5% |
EPIXEssa Pharma Inc
| 1.56% | $53.017M 8.749M shares@ $6.07 avg price | |
AGIOAgios Pharmaceuticals Inc
| 1.55% | $52.876M 1.19M shares@ $44.43 avg price |